Connect with us

Business

Why has the Telix (ASX:TXL) share price shot up 5% today?

Published

on

ADVERTISEMENT

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is racing higher after the company announced a new phase in its drug trials. The company confirmed it will proceed with the Phase III of ProstACT study for its TLX591 drug, a prostate cancer treatment.

The company also advised this morning that it has entered into a commercialisation and partnership agreement with DuChemBio, a leading South Korean radiopharmaceutical company.

At the time of writing, the Telix share price has surged up 5% to $4.20.

About the Phase III testing

Telix recently met with the United States Food and Drug Administration (FDA) to discuss the company’s planned Phase III ProstACT trial for TLX591. Today’s announcement is the result of that meeting.

The…



Click here to view the original article.

Continue Reading
Advertisement
Advertisement

Trending